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tlNo questions are unanswerable. 
Whatever curiosity the order of 
things has awakened in our minds, 
the order of things can satisfy." 
- Ralph Waldo Emerson 
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CHAPTER I 
INTRODUCTION AND STATEMENT OF THE PROBLEM 
An understanding of the mechanism of action of therapeutic agents 
in the body has been and stID remains one of the primary goals of bio-
chemical research programs. Such knowledge is an invaluable tool for the 
improvement in the quality of existing drugs as well as the discovery of 
new ones. It is important to know whether these agents act in the body in 
their original state or are perhaps transformed into some other compound 
which then can produce the desired effect. 
The knowledge of the mode of activity of antipyretic-analgetic agents 
in the body is far from resolved. An antipyretic compound is one that 
causes a reduction in the body temperature when a fever or abnormally 
high temperature is present. It has been known for a long time that anti-
pyretics a.ct to Increase the heat loss of the body rather than to decrease 
the body's heat production. This is accomplished by means of peripheral 
va.odUation, hydremia. polypnea., and espectally by an increase in the 
amount of perspiration. The exact mechanism by which this is accomplished 
remains somewhat obscure. Because the temperature regulating C81.ter is 
in the hypothalamus, it is Ukely that they influence this part of the tr~i1'\ in 
I 
-some manner, directly or indirectly. Yet. it is stUl not clear whether 
they affect this temperature reduction prior to a transformation in their 
chemical nature brought about by the activity or influence of some organ 
or system of the body. 
2. 
At the same time, certain of these compounds have exhibited un .. 
desirable side effects that have resulted, in some cases, in their use being 
discontinued. For example, 4-aminoantlpyrine, one of the most potent 
antipyretics, has exhibited the tendency to cause agranulocytosis, the white 
cell counterpart of aplastic or toxic anemia. In this disease there is an 
insufficient number of white cells produced by the body. A deeper insight 
into the mechanism of actton of this drug might reveal a cause not directly 
related to the drug but rather to some by-product, which could possibly be 
eliminated without dama.ging the property of antipyresis. This concept 
could certainly be extended to the other antipyretic compounds showing 
similar side effects. 
It was revealed some time back that this same compound, 4-amino .. 
antipyrine, acted as a catalyst in the decarboxylation of acetoacetic acid 
into acetone and carbon dioxide. In the human body this same reaction is 
catalyzed by the biologic enzyme, carboxylase. Thus, a laboratory 
synthesized compound acted in a manner similar to an enzyme, a. product 
of cellular metabolism. Further studies have revealed that there exists 
~~.---------------------------------------------------------------. 
other similarities between these two types of "catalysts". For this 
reason, compounds which act in this way are called "enzyme models". 
3 
It was found that the mechanism of action of the carboxylase enzyme 
is very much like the action of 4-aminoantipyrine, and further, that 
varying the environment as to pH and temperature also had similar effects 
on each. 
Experimental studies on other antipyretic compounds have been 
negative with regard to their ability to act as enzyme models. Investi-
gation of this problem has revealed that certain molecular arrangements 
are necessary for the compounds to act a.s organic catalysts for this 
decarboxyla.tion reaction. The other antipyretic compounds do not have 
this prerequisite as aminoantipyrine does. 
It remains quite possible, however, that in the human body these 
compounds are acted upon by an organ or system to bring about a trans-
formation in their chemical and structural nature prior to their action as 
antipyretic s. The antipyretic effect could stem from the fact that in the 
body they act as enzyme models of one type or another. The investigation 
carried out and discussed in the following pages repre.ents an attempt to 
determine if certain antipyretic compound. act a. organic catalysts for the 
decarboxylation of acetoacetic acid. It will also determine U these same 
compound. are affected by the activity of the liver and also yeast with re-
- 4 
spect to bringing about a transformation into a particular enzyme model. 
The first stage examines certain selected antipyretic compounds 
prior to any contact with any tissue or other substance found in the human 
body. In the second stage, ea.ch compound is incubated with yeast prior to 
testing. Yeast was used because it is a readUy available source of fermen-
tative enzymes and afforded an opportunity to see whether these glycolytic 
enzymes would have any e€fect on any of the antipyretic substances, It 
also enabled the operator to run through the incubation and testing procedure 
prior to the use of liver. which necessitated the sacrifice of an animal. 
The third stage was similar to the second except that liver was 
used in place of yeast. It is a known fact that many drugs are oxidized in 
the liver microsomes. and a study of foreign compounds has shown tllat a 
multitude of drugs are metabolized along a surprisingly few number of 
chemical pathways. Reduction of azo and nitro compounds, conjugation 
in the formation of glucuronides and other compounds, hydrolytic cleavage 
of esters and amides, as well as exchange reactions all take place in the 
liver. Thus, the liver was chosen as the most logical tissue which might 
affect this change in these chemical compounds, if this change does indeed 
occur. 
CHAPTER II 
REVIEW OF THE LITERATURE 
The concept of enzyme models is a relatively recent one. Von 
Wolfgang Langenbeck must be considered as one of the foremost piqneers 
in this field. In 1933, he demonstrated that several chemical compounds 
exhibited activity which had previously been known only to take place with 
biologic enzymes. Specifically, these compounds showed the ability to 
catalyze certain reactions which also occur in the body. For this reason 
the~ were designated as "enzyme models" or mimics. Further study re-
vealed an even greater similarity to certain enzymes with regard to their 
activity and the pH of the envi·ronment, the effect of chemical competitors 
on the speed of the reaction, and the specificity of both the substrate and 
the "enzyme model". He also found that the molecular size influences the 
potency of the catalyst, the more complex its molecular structure, the 
more powerful is its catalytic activity. 
· .. H2C-NH2 OH 
.. I C-NH 
COOH<' I 2 < 
. COOK 
Fig. 1. --MOLECULAR STRUCTURE COMPARED TO CATALYTIC 
ACTIVITY 
5 
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Widmark and Jeppsson are the only scientists who contributed to 
the literature with respect to enzyme models prior to the wor:k of 
Langenbeck. In the early 1920s th.ey made referenc'e to the fact that 
certain carboxylase active compounds behaved in a manner similar to 
organic enzymes with respect to hydrogen ion concentration. This result 
in the light of modern biochemistry is what one might expect. Following· 
their effort, further research was remarkably absent on enzymes like 
compounds until the work of Langenbeck. It was Langenbeck, however, 
who seemed to stimulate other research programs, particularly in Japan. 
In 1938, Kaneko presented his findings, the result of extensive re-
search with many compounds. He identified the relative catalytic activity 
of these compounds with their structural arrangement in an attempt to 
establish a correlation between the two. The results of his experiments 
are as follows: 
1. Aminophenol. 
a. Ortho-aminophenol showed little catalytic activity. 
,I ,,--
b. Meta-aminophenol showed some activity. 
c. Para-aminophenol was more active than the other two,. 
but not as' active as aniline. 
OH OH OH ONH2 <: ~H2 < 0 
NH2 
ortho- . meta- para-
7 
Fig. 2--AMINOPHENOL ISOMERS - RELATIVE ACTIVITY 
Fig. 3---ANILINE AND ANILINE WITH HYDROXYL GROUP ADDED 
d. The addition of an hydroxyl group had little effect on the 
activity of aniline. 
2. Phenyldiamine - 't'he order of activity is the same as aminophc;mol. 
< < c5 
NH2· 
ortho- meta- para-
Fig. 4 - -PHENYLDIAMINE ISOMERS - RELATIVE ACTIVITY 
3. Nitroaniline. 
a. Meta-nitroaniline is the most active. 
b. Para-nitroaniline is less active than meta-nitroaniline. 
c. Ortho-nitroaniline is the least active of the three. 
o~ > c5 > '&~ N0:3 
meta- para~ ortho-
Fig. 5--NITROANILINE ISOMERS - RELATIVE ACTIVITY 
8 
4. Aminobenzoic acid - the order of activity is the same as nitro-
aniline. 
o > ~ V eoCH 
COOH 
rneta- . para- ortho-
Fig. 6--AMINOBENZOIC ACID ISOMERS - RELATIVE ACTIVITY 
5. Aminobenzine sulfonic acid - the order of activity was the same 
as aminobenzoic acid. 
> 
rneta- para- ortho-
Fig. 7 - -AMINOBENZINE SULFONIC' ACID ISOMERS - RELATIVE 
ACTIVITY 
6. Methylaniline or toluidine. 
a. Meta-toluidine was 1-1/2 times more active than aniline. 
I /._' 
b. Ortho-toluidine and para-toluidine were less active than 
aniline. 
6 (3 c5 > > CH3 H3 
CH3 
rneta- para- ortho-
9 
Fig. 8--TOLUIDINE ISOMERS- RELATIVE ACTIVITY 
7~ . Xylidine. 
a. Ortho and para-xylidine were as potent as aniline. 
b. Meta showed little activity. 
OH3 OH3 0 c:..-"J . > NH2 NH2 
NH2 CHJ 
ortho- para- meta-
Fig. 9--XYLIDINE ISOMERS.- RELATIVE ACTIVITY 
8. Toluidine diamine and amidol or diaminophenol were very active. 
(a) (b) 
ONH2 (r~ 
N~ N~ 
Fig. lO--TOLUIDINE DIAMINE (a) AND AMIDOL (b) - RELATIVE 
ACTIVITY 
9. Methyl aniline and methol showed little activity. 
(a) 
Fig. ll--METHYLANILINE '(a) AND METHOL (b) 
10. Dimethyl -p- phenylendiaminewas catalytically active. QCH3)2 
Fig. 12--DIMETHYL -p- PHENYLENDIAMINE 
11. Aminonaphthalene. 
l 
a. alpha aminonaphthalene was stronger than aniline. 
b. beta aminonaphthalene was weaker than aniline. 
alpha beta 
Fig. 13--AMINONAPHTHALENE ISOMERS 
12. Hydrozine - proved to be inactive. 
. Fig. 14--HYDROZINE 
l 
, , 
13. Generally speaking, the aromatic hydrocarbons are far better 
organic catalysts than the alaphatic. 
10 
a. Aminocyclohexane is an example .of an alaphatic hydrocarbon 
which is inactive. 
~~ 
....... C ..... 
C C 
I I 
C ..... ,.C 
C 
Fig. 15--AMINOCYCLOHEXANE 
11 
14. Ethylene diamine is an alaphatic hydrocarbon which is active as 
an organic catalyst. 
H H 
H2 N-C-C-NH2 H H 
Fig. l6--ETHYLENE DIAMINE 
15. Pyridine. 
a. Alpha pyridine is slightly active. 
b. beta pyridine is inactive. 
alpha beta 
Fig. 17 - -PYRIDINE ISOMERS 
16. ,I .':...---Aminopyrine proved to be inactt;ve. 
. NH3 C ... CH3 
-- .. ~·.II . V \) C-N(CHaJ2 
Fig. lB--AMINOPYRINE 
12 
17. Aminoantipyrine is not only an excellent catalyst for the 
decarboxylation of acetoacetic acid, but also pyruvic acid •. 
H3C-C-C-oH 8 8 
Fig. 19--PYRUVIC ACID. 
It was Kuga in 1941 who noted that in addition to the basic 
molecular structure, the enzyme model must contain certain other 
groups. The nature of these side groups greatly influences the effec-
tiveness of the catalyst, 'as one might expect. 
Fig. 20--KUGA'S BASIC MOLECULAR STRUCTURE OF AN 
ENZYME MODEL 
Of particular significance is the fact that when this group was 
, ,.--
associated with a group structurally similar to the keto acids, such as 
amino derivatives of pyrazalone and amino-methyl-uracil, they showed 
definite catalytic activity. 
He further revealed that the activity of the enzyme models is in 
direct proportion to the relationship between the dissociation constants of 
the c'atalysts and keto acids. Thus, if the dissociation constant of the 
13 
enzyme model1s relatively high, the constant of the acid must also be 
high for the effective. ?erformance of the catalyst. 
Studies by Akamatsu and Fukuda substantiated the work of Kaneko 
and Kuga. Fukuda indicated the presence of an acetoacetic residue in the 
a.minoantipyrine molecule. 
Fig. Zl--AMINOANTIPYRINE MOLECULE INDICATING THE 
ACETOACETIC ACID RESIDUE 
It was found that all of the enzyme models contain a free amino 
group in the alpha carQon position; the beta carbon of the molecule com-
bines with the N of another molecular group. The free amino group ap-
pear.s to be the key to the me chanism, which may be to increas-e the 
aff.inity between the catalyst and substrate. The beta keto catalysts re-
sulting in a substrate with an unstable carboxyl which dissociates; the 
remaining Shiff's base either dissociates spontaneously to pr·oduce the 
,I , .. -
original free catalyst or reacts successively with a second molecule of 
acetoacetic acid under acetone liberation. ~<:'c'CHJ 
H C ON~~ II CH3 . He· ~ b. rf-H3 ..cH3 ~\-C ..... N=c . 3N-{H3 p-13 
lOr<' -~ :. 0 ~4 --;..A,-C'N + y=o ~f ~ .. + ()'t.oC N~ 9=0 UO H2 CH3 
~ ~ . 
OH 
Fig. ZZ--CATALYTIC DECARBOXYLATION OF ACETOACETIC 
ACID BY AMINOANTIPYRINE 
14 
Beniya had already observed in 1934 that a second amino group 
in the neighboring position intensifies the decarboxylation activity~ The 
subsequent investigation of Fukuda and Kumiga showed similar results. 
In these heterocyclic diamino compounds there is no more acetoacetic acid 
residue, because a methyl has been exchanged with another amino group. 
It is kn<?wn, however, that an amino group behaves electrically the (same 
\ 
as a methyl group. 
Akamatsu noted that amino-oxindol is an intensive catalyst for 
alpha keto acid decarboxylation, yet it is scarcely active to acetoacetic 
acid, probably owing to the absence of beta keto acid residue. The beta 
carboxylase model, he remarked, must contain a free amino, and more-
over a structurally analogous residue for the enhancement of the activity. 
This activity, on the other hand, is also dependent upon the other part of 
the catalyst l s molecule. He also noted regular variation in catalytic power 
in different heterocyclic compounds. 
In 1952., Schadt, Becker and McLaren of the Department of 
Chemistry of Polytechnic Institute of Brooklyn studied the thermal cata-
lyzed decarboxylation of phenylglyoxylic acid of 3-amino alpha naphthindole 
at 70 degrees. They remarked that the kinetics and me'chanism of the 
catalytic action of model substances having enzyme-like activity may be 
of interest if the information acquired can be applied to the mode Ol action 
15 
of natural enzymes. The theoretical mechanism of the catalytic decar-
boxylation of a keto acid by a carboxylase model was proposed as follows: 
1. INITIATION. 
('r-1-N'Y.! + 
~~.I~ N 
H 
Z. REARRANGEMENT. 
0:
, 5=H3, 
r=N-C 
wC''o A, 
H ···HO 0 
3. CLEAVAGE. 
?H3 
0: ~H3 O:c1 -N_CH C=N--cH + cn.... I I ---~> r ......-" N ..... ~ N"~bl\\ H 
H ···HO 0 
4. FURTHER REACTION OF SHIFF BASE WITH PYRUVIC ACID. 
Fig. Z3--THE THEORETICAL MECHANISM FOR THE CATALYTI 
DECARBOXYLATION OF A KETO ACID BY A CARBOX-
YLASE MODEL 
The proximity between the carbonyl oxygen of the Z -carbon and 
the carboxyl hydrogen, making hydrogen bonding possible was noted at this 
time. As proposed in the above scheme, hydrogen bonding between the 
-16 
oxygen and hydrogen atoms probably precedes decarboxylation. 
The authors then discussed the kinetics of the decarboxylation of 
pheny1g:i.ocylic acid oy 3-amino a.lpha-naphthoxindole. The mechanism for 
the reaction is as fo How': 
1. INITIATION. 
Z. DECARBOXYLATION. 
O~NR ___ ~~ QbNR + CD2 
OH 
3. REGENERATION • 
. ~ V =NR'+ 
4. TERMINATION. ,., 
Fig! Z4--THEORETICAL MECHANISM FOR THE DECARBOXY-
LATION OF PHENYLGLOCYLIC ACID BY 3-AMINO-
ALPHA -NAPHTHOXINDOLE 
17 
Pederson proposed the following mechanism for the decarboxy-
lation of beta ketocarboxylic acids: The ordinary form 'of the undissociated 
acid (I) is stable. The acetoacetate ion (II) decomposes verY' slowly. Owing 
to the weak basic properties of the keto group, it will, to a \Small extent, 
, J 
take, up the hydrogen ions. The conc'entration of the ampho ~on (III), thus 
formed, is proportional to the concentration of the ordinarYiundissociated 
- ' 
acid. Consequently, it is impossible to decide from the kinetic experiments 
which of them is unstable. Owing to the attraction of the positive charge, 
, " 
it is reasonable to assume that the ampho ion de~omposes much more 
quickly than the ion (II). By the decomposition we get the erfol form of the 
rea.ction product (I,V).' 
I II III IV 
H3CH3? H3Y 
, t=O c=o C=OH+ 
I I I 
H2 C H2 Y H2 Y 6=0 y=O C=O bH 0- b-
+ CO2 
Fig. 25--REACTION KINETICS FOR THE DECARBOXYLATION ·OF 
BETA KETOCARBOXYLIC ACIDS 
• . I /. __ . 
In order to explain the amine catalysis we assume that an 
equilibrium of the type 
is quickly established. The group CNR has much .stronger basic 
properties than the keto group. Although the substance CNR: may only be 
formed in a very small concentration bv eauilibrium {n to BllcycypM ~. 
- .... * .-
18 
greater concentration of ampho ion than before, and a quicker decomposi-
tion. 
Westheimer, in 1959, studied the l'nechanism of the enzymatic 
decarboxylation of acetoacetate by examining the oxygen exchange which 
accompanies the decarboxylation, labeled in the carbonyl group with 018 , 
in the presence of the crystalline decarboxylase from Clostridium aceto-
\ 
butylicum. 
His experiments showed that the exchange of 018 from the carbonyl 
group of acetoacetate is an obligatory part of the enzymatic decarboxylation 
process; control experiments establish that the direct exchange of 018 fro~ 
acetone and aceto~cetate, in the presence or absence of enzyme, is incom- : . 
. . . 
plete. The results are con~istent with the. hypothesis that the reaction pro-
ceed.s by way of Shiff base formation between the ketoacid and. the enzyme, . 
but do not themselves demand thi,s conclusion. This mechanism is very 
similar to the one proposed by Pederson for the non-enzymatic amine 
catalyzed decarboxylation of acetoacetate. 
There are additional scientists, Cramer, Kampe, Mix, Shimoda 
and others, who have studied and carried out experiments with enzyme 
. .' J 
:models. Their work, however valuable it may be, extends,beyond the 
rather specific scope of this thesis. Yet, I feel in conscience ,the necessity 
to recognize their work before passing on to the next topic •. 
19 
ANTIPYRETICS 
There have been several valuable clinical studies on the trans-
formations which certain antipyretic compounds have shown to exhibit in 
the body. The overwhelming amount of work has been carried out by 
Bernard B. Brodie and his associates. He studied acetanilide, aceto-
I 
phenetidine, antipyrine, and aminopyrine. 
The route of acetanilide in man was shown to be as follows: a 
minor fraction of the drug deacetylates to form aniline: this compound 
was shown to be a precursor of the substance which oxidizes hemoglobin 
to methemoglobin; the major fraction of the drug is oxidized to N -acetyl 
p-aminophenol; this compound is excreted in a conjugated form.' The anal-
gesic action of acetanilide is exerted mainly through N-acetyl p-aminophenol 
which is an active analgesic. The oxidation of acetanilide occurs mainly in 
the liver. 
Q. 
-C,CH3 
. ) "0 
f. R ,i---. ~-CH3 ~} c)~---.... cr 
Fig. z6--TRANSFORMATION OF ACETANILIDE IN MAN 
The route of ' metabolism of' acetophenetidin in man;id.follOWS: 
The major fr'action of the drug is rapidly deethylated to N -acetyl p-amino-
20 
phenol; this compound is excreted in a conjugated form; a minor fraction 
deacetylates for form p-phenetidin; this compound was shown to be a pre-
cursor of the .ub.t&nl;;e which oxic1bes h0m(;'Jglobin 1..0 nH:~th"n'loglo'bin. 
The analgesic and antipyretic action of acetop!1enetidin is exerted mainly 
through N -acetyl p-aminophenol which is an active analgesic and antipyretic. 
'QHN-C-<H3 
'b 
----------------------~ 
H 
~CH3 
~~H 
OHN-
CbCH3 ;:.. NH2/ OR 
H H _~ 
Fig. 27--TRANSFORMATION -~HACETOPHENETIDIN ~ MAN, 
The, route of metabolism of antipyrine in man was shown to be as 
follows: 30 - 40 % of the drug is oxidized to 4-hydroxyantipyrine, which is 
quickly conjugated with glucuroned and possibly sulfuric acid and excreted 
as such; the remainder of the antipyrine is metabolized through an unknown 
route. ' 
Pyramidon (dimethylamino pyrine) was discontinued as a thera-
peutic agent due to an occasional occurrence of ii-grCl:Ilulocytosis following 
its use. It does not cause methemoglobinemia or disturbance of RBCs or 
ci'Luse gastric distress sometimes associateG with the salicylates. The 
drug is absorbed almost completely from the gastrointestinal tract and is 
fairly evenly distributed throughout the body water. 
in the urine, the rest being transformed in the body .. 
Only 30/0 is excreted 
The ;:;"Iof transf!,,-
mation varies from 10 - 300/0 an hour in different individuals. 
21 
A major step in the rr:etabolism of Pyrarnidon in man involves 
demethylation to form 4-aminoantipyrine, a,l active analgesic and anti-
pyretic. This compound is acetylated in la.rge parI; to J\ -acetyl 4-amino-
antipyrine, which seems to be pharmacologically inert. A minor fraction 
of Pyramidon is converted to 4-hydroxyantipyrine, which is excreted in a 
conjugated form. About 500/0 9£ the Pyramidon is unaccounted for.· 
The analgesic and.antipyretic activity of Pyramidon is exerted 
only in part through 4-aminoantipyrine; it is probable that the parent com-
Fig. 28--TRANSFORMATION OF AMINOPYRINE IN MAN 
Boreus and Sandberg concluded. following their experiments with 
acetophenetidin and N-acetyl p-a.mino~henal. th.~.latte~ compound was 
found to exert about the same analgeslc and anhpyretfc achon as aceto-
phenetidin but to have a lower toxicity and a smaller methemoglobin pro-
ducing effect. 
zz 
Barbour, one of the original researchers of antipyretics, 
attempted to evaluate the clinical signs of aspirin antipyresis in normal, 
and fevered individuals. He noted that acetylsa.licylic acid did not seem to 
have any ef'iect on persons with normal, temperature values. However, 
there was a definite increase in the amount of heat loss when this anti-
pyretic was administered to the individuals with elevated temperatures. 
This was accomplished by peripheral vasodilation, hydremia, polypnea 
and especially by an increase in the production of perspiration by the body. 
Guerra and Barbour, working with monkeys, discovered essen-
tially the same thing. Further research by Guerra and Brobeck showed a 
marked liability of temperature regulation in monkeys following the estab-
lishment of lesions in the anterior and anterolateral hypothalamus. This, 
however, did not alter the rate of decline of fever pr'oduced by yeast injec-
tion following aspirin administration. 
As in the case of enzyme models, additio~esearch has been 
car~ied out, but the above mentioned projects represent the highlights, of 
the programs carried out to date and indlcates th~ current thinking 0Ll the 
activity at the molecular and clinical levels. 
There have been no projects to da.te attempting to d,etermine if the 
liver has an'y: effect on these antipyretic compounds with respect to the 
formation of enzyme' models. ' 
CHAPTER THREE 
EXPERIMENTAL PROCEDURE 
1. ANTl,PYRETlC CONSTITUENTS OF THE TESTING PROGRAM. 
A. 4-Aminoantipyrine 
1. Molecular Structure 
2. Molecular Weight - 203.2 
B. Acetamidoantlpyrine (4-acetyl aminoantipyrine) 
1. Molecular Structure 
2. Molecular Weight - 245.2. 
C. N -Acetyl p-aminophenol 
1. Molecular Structure 
2. Molecular Weight .. 151.2 
23 
D. 3 -Hydroxyacetanilide 
1. Molecular Structure 
2. Molecular Weight - 151. 2 
E. P-acetphenetidine 
1. Molecular Structure 
~-CH) 
V OH 
(jHN g-CH:3 
fjl 
O-y-CH:3 
2. Molecular Weight - 171. 2 H 
F. AcetoacetanUide 
1. Molecular Structure 
2. Molecular Weight .. 177.2 
G. Acetylsalicylic Acid 
1. Molecular Structure 
2. Molecular Weight - 180.15 
H ;;Y- ,-fi- CH:3 V H 0 
24 
*Structure in red indicates where it differs from 4-a.minoantipyrine 
U. TESTING PROCEDURE 
A. Introduction 
25 
These seven antipyretic compounds were tested for their ability to 
catalyze the decarboxylation of acetoacetic acid. The reaction products a.re 
acetone and carbon dioxide. The ra.te of the reaction is determined by 
measuring the pressure differential produced by the carbon dioxide gas 
emitted. 
This is accomplished through the use of the Warburg Respirometer, 
an instrument which facUitates a high degree of control over the tempera" 
ture of the solutions during the testing periods and ensures a uniform agi-
tation of the fia.ks. 
B. Stage One 
1. Preparation of the Solution. 
In this first stage, one half of the molecular weight. in milligrams, 
of each of the antipyretic compounds is dissolved in fifty milliliters of dts-
tilled water, making a lOmM solution. This is designated as solution A for 
purposes of explanation. 
The acetoacetic acid is prepared by adding 1. 0 mUliliter, of 
acetoacetate methyl ester and five mUliliters of 2N NaOH to a fifty milli-
liter volumetric fiask. diluted to volume and allowed to stand at room 
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temperature for two hours. 
~ ~ ~ ~ 
HC-C-C-C-O-C-CH dil alkali :> 
I II I II I I 
H 0 H 0 H H 
H 
HC-C- C- C-Na dB. acid 
II I " o H 0 
) 
~ <j{ $? 
Hr-C - C- C- OH 
y 11 
Fig. 29-·REACTION ~R ACETOACETIC ACID PREPARATION 
It was found that after a twenty-four hour period had elapsed, a 
considerable amount of spontaneous decarboxylation had taken place. If 
used, the solution would mimic the results present when catalysts is actu ... 
ally occurring. For this reason, a fresh solution of acetoacetic acid was 
prepared on testing days. 
~ ~ ~ ~ 
HC-C-C-c-::-Oi:-l-., --,->",HC:-:"C-..:-.. CH,+ .. CQ~, .. " .. _ 
I II I II I II I 
HOHO HO H 
Fig. 30 ..... SPONTANEOUS DECARBOXYLATION OF ACETOACETIC 
ACID 
The only other constituent of the initial phase is sodium acetate 
buffer, which has been adjusted to a pH of 4.2 and is designated as solution 
B. 
2. Preparation of the Warburg Flasks 
The first two Warburg flasks, designated 1 and lat were prepared 
in the following manner: five milliliters of a 1:4 ratio of solution A to solu .. 
tion B were added to the main flasks, while one millUiter of acetoacetic acid 
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was placed in each side arm. The second pair of flasks, designated 2 and 
2a, also contained one millUiter of acetoacetate in ea.ch of the side arms. 
However, to each main flask was added five mUIUiters of a 1:9 ratio of 
solution A to solution B. The third pair of flasks, designated 3 and 3a. 
acted as controls and contained five millUiters of distUled water in each 
main flask and one mUliliter of a.cetoa.cetate in the side arms. 
3. Procedure of the Initial Phase 
The side arms of the flasks were stopped and attached to the six 
manometers, which were then secured to the side of the water bath drum, 
making certain that the water level was sufficiently high to cover the flasks. 
The solutions were equUibrated for five minutes in the water bath at 37 de-
grees. Following this, the contents of the stde arms were added to the main 
flasks and the systems closed. The pressure differential produced by the 
carbon dioxide was recorded every five minutes for thirty minutes. The 
control figures were subtracted from the figures of the main test in order 
to accurately determine any ca.talytic activity present. 
Thh procedure was carried out twice for six of the seven com ... 
pounds. The only deviation from this program came in the case of P-acet .. 
phenetidine, where it was found that one half of molecular weight in mUli-
grams would not dissolve in fifty mWUiters of distUled water. In this case, 
ethyl alcohol was used as the solvent in the same quaItity a.s the wa.ter had 
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been used for other preparations. It was necessary, therefore. to run an 
additional experiment using ethyl alcohol without the acetoacetic acid to 
determine the pressure differential produced by this compound alone. ThiB 
figure was subtracted from the main test. 
c. Stage Two 
1. Preparation of the Solutions 
As in the first step, one half of the molecular weight of each com-
pound was used. This was added to twenty five milliliters of distilled water 
along with one gram of glucose, one gram of yeast and five hundred mUli .. 
grams of sodium phosphate. The contents were then placed in the fifty 
milliliter volumetric flask and dUuted to volume. An aliquot (10 milliliters' 
was certrifuged immediately. The remaining. larger part of the solution 
was incubated at 37 degrees for twenty-four hours. Following incubation, 
this too was centrifuged. The superna.tants of the centrifuged aliquot and 
the incubated sample were designated as solutions A and AI. respectively. 
The acetoacetic acid and sodium acetate buffer preparations were 
identical to stage one. 
The only exception to the above preparations was, as in the first 
stage, P-acetphenetidine. The ethyl alcohol. however. would be imprac-
tical for the second stage, for it would interfere with the normal biochemi-
cal processes during incubation. Thus, one half of the molecular weight in 
milligrams of this compound was dissolved in one hundred mUlUiters of 
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water following the addition of yeast, glucose and sodium phosphate as with 
the other compounds. 
In order to have the same number of milliequivalents reacting with 
the acetoacetic acid as the other compounds, it was necessary to double the 
amount of solution in the Warburg flasks. Thus, ten milliliters of 1:4 and 
1:9 ratios of solution A Cl" AI, to solution B were used. 
Z. Prepara.tion of the Warburg Flasks 
The flasks were prepared in the same manner as in stage one with 
respect to solution ratios and amounts. The only exception to this is the 
above mentioned P"acetphenetidine. 
3. Procedure of the Second Stage 
The deviation in the program from the first stage is a result of the 
incubation of the solutiOl.1.s. Each ...:ompound was first tested for catalytic 
activity following initial contact with the yeast. Here. an aliquot was cen-
trifuged immediately and tested in the same manner as the compounds of 
stage one. The remaining part was first incubated for twenty .. four hours 
and then centrifuged and tested. Thus. the ca.talytic activity of each com .. 
pound was determined before and after the incubation process. 
D. Stage Three 
1. Preparation of the Solutions 
In the final stage, liver was used in place of yeast. Thus, a liver 
weighing nine gram was removed from a. freshly sacrificed rat and placed 
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in a Waring Blender together with ninety milliliters of water. The ingredi-
ents were then blended until a homogeneous mixture was obtained. This was 
divided into nine equal parts of terA milliliters each. Since the concentra-
tion of the mixture is one gram per ten milliliters. each part represents 
one gram of liver. They were stored in the freezer until such time as 
needed. The remaining preparations were identical to the ones of stage two. 
2. Preparation of the Warburg Flasks 
This was done in the same manner as stage two. 
3. Procedure of the Third Stage 
This was also the duplicate of the second stage. 
GUIDE TO GRAPHIC ILLUSTRATIONS 
A. SINGLE COMPOUND GRAPHS 
Initial 
Before Incubation 
After Incubation 
B. COMPARATIVE GRAPHS FOR AN ENTIRE STAGE 
4 -Am inoantipyrine 
Acetylsalicylic Acid 
Acetamidoantipyrine 
3 .. H ydroxyacetanUide 
Acetoacetanilide 
N ... Acetyl p-Aminophenol 
P -Acetphenetidine 
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CHAPTER FOUR 
EXPERIMENTAL FINDINGS 
1. Stage One 
A. 4 - AminoanUpyrine 
Fla.sk Numbers 
1 la. 2 2a 3 3a 
5 24.9 24.4 16.5 19.0 0.2 0.2 
M 10 19.1 19.6 14.5 13.5 0.2 0.1 
i 
n 15 13.2 12.9 13.1 11.8 0.1 0.2 
u 
t 20 13.8 14.6 12.9 11.8 0.2 0.1 
e 
s 25 13.8 13.2 8.6 7.9 0.0 0.2 
30 8.4 7.6 
..!:..L .1:..Q.. 0.2 g 
- - -93.2 92.3 74.7 73.0 0.9 1.0 
4 .. Aminoantipyrine 
Flask Numbers 
1 1a 2 2a 3 3a 
5 30.0 29.6 18.8 22.3 0.5 0.8 
M 10 22.4 20.3 13.4 11.5 0.3 0.2 
i 
n 15 18.5 17.9 12.0 12.0 0.1 0.4 
u 
t 20 15.4 16.7 12.3 11.5 0.1 0.1 
e 
s 25 5.7 7.0 11.0 11.8 0.2 0.2 
30 4.2 4.5 6.5 5.7 0.1 0.1 
96.2 96.0 - 74.8 - -74.0 1.3 1.8 
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B. Acetylsalicylic Acid 
Flask Numbers 
1 1a 2 2a 3 3a 
5 2.2 2.0 2.1 2.5 0.2 0.3 
M 10 0.7 0.7 0.7 0.7 1.0 0.1 
i 
n 15 0" 5 0,5 0.4 0.5 0.1 0.2 
u 
t 20 0.4 0.3 0.4 0.3 0.1 0.0 
e 
s 25 0.5 0.4 0,2 0.2 0.0 0.1 
30 0.4 0.5 °t 2 0.2 0.0 0.0 
- - - r:4 -4.7 4.4 4.0 4.4 0.7 
Acetylsalicylic Acid 
Flask Numbers 
1 1a 2 2a. 3 3a 
5 2.2 1.4 1.1 2.1 0.2 0.3 
M 10 0.5 1.8 1.1 0.7 0.1 0.1 
i 
n 15 0.4 0.6 0.8 0.6 0.0 0.1 
u 
t 20 0.3 0.6 0.5 0.5 0.1 0.0 
e 
s 25 0.3 0.4 0.4 0.2 0.0 0.0 
30 0.2 0.2 0.1 0.2 0.1 0.1 
- - - - -3.9 5.0 4.0 4.3 0.5 0.6 
c,\400L O~ 
( "; LOYOLA I UNIVERSITY 
.~" ..... '" ,«,........ ., ..... / 
. I: .-~ 
'! f , 'to"\ .N 
"'"",........ " . ~ __ " .. ,~r· 
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C. Acetamidoantipyrine 
Flask Numbers 
1 la 2 2a 3 3& 
5 1.4 1.7 1.9 1.8 0.1 0.0 
M 10 0.5 0.7 0.8 0.5 0.0 0.1 
i 
n 15 0.6 0.5 0.2 0.4 0.1 0.1 
u 
t 20 0.6 0.9 0.2 0.3 0.1 0.0 
e 
s 25 0.3 0.2 0.4 0.4 0.1 0.0 
30 0.5 0.4 0.3 0.2 0.0 0.0 
- - - - - -3.9 4.4 3.8 3.6 0.4 0.2 
A cetam idoantipyrine 
Flask Numbers 
1 la 2 2a. 3 3a. 
5 1.5 1.6 1.1 1.1 0.2 0.4 
M 10 1.0 0.5 0.5 0.7 0.0 0.0 
i 
n 15 0.5 0.4 0.5 0.6 0.3 0.0 
u 
t 20 0.3 0.5 0.3 0.2 0.0 0.0 
e 
s 25 0.6 0.5 0.5 0.5 0.1 0.1 
30 0.4 0.2 0.3 0.4 
.2.d 0.1 
- - - -4.3 3,7 3.2 3.5 0.7 0.6 
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D. 3 - HydroxyacetanUide 
Flask Numbers 
1 la 2 2a 3 3a 
5 4.2 4.7 3.2 3.4 0.4 0.5 
M 10 0.7 0.5 1.0 1.1 0.4 0.4 
i 
n 15 0.4 0.5 0.6 0.6 0.3 0.4 
u 
t 20 0.3 0.7 0.6 0.4 0.3 0.1 
e 
s 25 0.3 0.5 0.3 0.6 0.1 0.2 
30 0.3 0.2 0.3 0.2 0.3 0.1 
6.2 - - - - -7.1 6.0 6.3 1.8 1.7 
3 - Hydroxyacetanilide 
Flask Numbers 
1 la 2 2a 3 3a 
5 2.3 2.5 2.1 2.0 0.2 0.1 
M 10 0.9 0.7 0.9 0.7 0.0 0.1 
i 
n 15 0.8 0.6 0.4 0.4 0.1 0.2 
u 
t 20 0.7 0.6 0.3 0.5 0.1 0.1 
e 
s 25 0.4 0.5 0.5 0.3 0.1 0.0 
30 0.4 £:.! 0.2 g 0.0 0.1 
- - - 0.6 5.5 5.3 4.4 4.1 0.5 
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E. AcetoacetaniUde 
Flask Numbers 
1 1a 2 2& 3 3& 
5 2.9 2.6 2.7 2.5 0.2 0.2 
M 10 0.6 0.8 0.9 0.9 0.2 0.1 
i 
n 15 0.7 0.7 0.8 0.6 0.1 0.1 
u 
t 20 0.7 0.6 0.6 0.4 0.2 0.1 
e 
s 25 0.6 0.5 0.5 0.4 0.0 0.0 
30 0.3 0.3 0.3 0.3 0.1 0.1 
5.8 - 5.8 IT o:B -5.5 0.6 
AcetoacetanUide 
Flask Numbers 
1 1a 2 2& 3 3& 
5 2.9 3.5 2.2 2.0 0.4 0.3 
M 10 1.1 0.9 1.3 1.0 0.1 0.2 
i 
n 15 0.7 0.5 0.4 0.6 0.1 0.0 
u 
t 20 0.5 0.6 0.6 0.5 0.0 0.1 
e 
s 25 0.4 0.4 0.4 0.4 0.1 0.1 
30 0.3 0.4 0.3 0.4 0.0 0.0 
- 6.3 - - - -5.9 5.2 4.9 0.7 0.7 
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F. Acetyl - e .. Aminoeheno1 
Flask Numbers 
1 1& 2 2& 3 3& 
5 1.9 1.8 1.8 1.7 0.1 0.0 
M 10 0.9 0.8 0.8 0.7 0.2 0.1 
i 
n 15 0.6 0.9 0.6 0.5 0.2 0.2 
u 
t 20 0.5 0.6 0.5 0.7 0.1 0.1 
e 
s 25 0.5 0.4 0.4 0.3 0.0 0.1 
30 0.4 0.4 Q!l. 0.3 0.1 0.1 
- - - - 0:6 4.8 4.9 4.4 4.2 0.7 
Acetyl - e .. Aminophenol 
Flask Numbers 
1 1a 2 2& 3 3& 
5 2.3 2.6 2.1 2.3 0.3 0.3 
M 10 0.7 0.6 0.8 0.8 0.2 0.3 
i 
n 15 0.6 0.7 0.6 0.6 0.0 0.1 
u 
t 20 0.9 0.7 0.5 0.5 0.1 0.2 
e 
s 25 0.3 0.3 0.5 0.6 0.2 0.0 
30 0.3 0.3 0.2 0.1 0.0 0.1 
- - - - - -5.1 5.2 4.7 4.9 0.8 1.0 
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G. P-Acetphenetidine (using ethyl alcohol as the solvent rather than 
water) 
Flask Numbers 
1 1a 2 2a 3 3a 
S 4.5 4.5 4.2 3.9 0.4 0.5 
M 10 2.0 2.0 2.3 2.0 0.3 0.1 
i 
n 15 1. 5 1.3 1.4 1.2 0.1 0.2 
u 
t 20 1.9 1.9 1.5 1.5 0.2 0.2 
e 
s 25 2.0 1.9 1 .. 1 1.2 0.2 0.3 
30 1.6 1.6 1.0 1.1 0.2 0.1 
- - - - IT -13.5 13.2 11. S 10.9 1.4 
P -Ace!phenetidine 
Flask Num be r s 
1 1a 2 2a 3 3a 
S 6.2 6.6 5.6 5.8 0.7 0.6 
M 10 2.5 2.8 2.0 2.2 0.5 ' 0.5 
t 
n 15 2.3 2.3 2.0 2.0 0.4 0.2. 
u 
t 20 1.8 1.7 1.5 1. 7, 0.3 0.3 
e 
s 25 2.3 2.2 1.0 1.0 0.1 0.2 
30 0.9 1.2. 1.1 1.1 0.1 0.1 
16.0 i'6.8 - - IT -13.2. 13.8 1.9 
M 
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H. The following test is used to determine the amount of pressure 
i 
n 
u 
t 
e 
caused by the ethyl alcohol during the experiment with P-Acetphene .. 
tidine. The contents of the flasks are as follows: 
A. The Central Unit of Main Flask 
B. 
s 
a) Flasks numbered land la contain 5ml. of the following 
solution: 
(1) sodium acetate buffer adjusted to ph 4.2 
(2) 1:5 dUution of ethyl alcohol. 
b) Flasks numbered .2 and 2a contain 5ml. of the following 
solution: 
(1) sodium acetate buffer adjusted to ph 4. 2 
(2) 1:10 dUution of ethyl alcohol. 
The Side Arms - All of the flasks contain Iml. of distUled water 
in the side arms. 
Flask Numbers 
1 la 2 2a 
5 2.5 2.7 2.5 2.1 
10 1.0 0.6 0.3 0.3 
15 0.5 0.3 0.0 0.1 
20 0.4 0.3 0.2 0.2 
25 0.6 0.2 0.4 0.3 
30 0.4 0.4 0.1 0.2 
- - - -5.4 4.5 3.5 3.2 
30 
. , 
... 
10 
9 
8 
7 
6 
~ . 5 
J 4 
3 
2 
. ' 
pa.uTlOIIl:I t 
5 . .., ·18 2b 
__ .\ twE hlllllllt,,) , 
mm. of 
PRESSURE 
j' 
• 
,0 D IS 20 iii 
TIME (mirilltlll' 
---
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II. Stage Two 
Note ... The following differentiation is used in this stage: 
Part A .. Before incubation 
Part B .. After incubation 
A. 4 ... Aminoantipyrine. Part A 
Flask Numbers 
1 1a 2 2a 3 3a 
S 24.9 22.3 16.6 15.8 0.1 0.2 
M 10 22.4 20.9 18.0 16.5 0.0 0.1 
i 
n 15 13.8 14.2 11.1 13.4 0.1 0.1 
u 
t 20 7.4 8.0 10.0 U.7 0.0 0.2 
e 
s 2.5 8.6 9.2. 13.2. 13.9 0.1 0.1 
30 5.3 5.4 8.1 8.0 0.0 0.0 
- - - - - -82..4 80.0 77.0 79.3 0.3 0.7 
4 .. Aminoantipyrlne. Part A 
Flask Numbers 
1 la 2 2a 3 3. 
5 20.1 2.5.9 15.6 19.5 0.2 0.2 
M 10 24.5 24.4 18.5 18.5 0.2 0.1 
i 
n 15 14.2 14.0 13.9 ll.9 0 .. 0 0.0 
u 
t 20 10.4 10.0 10.4 8.3 0.1 0.0 
e 
s 25 9.7 9.2 10.8 10.9 0.1 0.1 
30 
.!:2. 6.0 8.2 8.1 0.0 0.0 
- - - - -85.4 89.5 77.4 77.2 0.6 0.4 
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4 ... Amlnoantipxrine. Part B 
Flask Numbers 
I la 2 2a 3 3a 
5 23.1 26.1 17.0 15.8 0.3 0.2. 
M 10 20.0 23.0 18.9 16.2 0.1 0.1 
i 
n 15 15.0 14. <) 15.6 15.7 0.0 0.2 
u 
t 20 11.8 12.0 9.5 10.4 0.1 0.1 
e 
s 25 7.0 5.6 10.0 10.8 0.0 0.0 
30 4.5 4.0 8.1 8.7 0.0 0.0 
- 85.6 - "ff:6 - 0.6 81.4 79.1 0.5 
4 ... Aminoantipyrine. Part B 
Flask Numbers 
1 la 2. 2a 3 3a 
S 22 •. 4 23.0 15.5 14.8 0.3 0.2 
M 10 2.1.5 22.0 13.4 11.5 0.0 0.1 
i 
n IS 13.7 13.5 14.5 14.4 0.1 0.0 
u 
t 20 14.2 14.0 14.0 14.1 0.0 0.0 
e 
s 25 7.3 7.9 13.5 13.4 0.1 0.1 
30 6.4 6.5 7.4 8. Z. 0.1 0.0 
- - - - 0.6 -. 85.5 86.9 78.3 76 .. 4 0.4 
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B. Acetylsalicylic Acid. Part A 
Flask Numbers 
1 la 2. 2.a 3 3a 
5 4.0 1.5 2..0 1.6 0.1 0.2. 
M 10 0.7 1.0 0.9 1.0 0.1 0.2. 
i 
n 15 0.6 0.8 0.7 0.7 0.0 0.0 
u 
t 2.0 0.3 1.0 0.6 0.5 0.1 0~2. 
e 
s 2.5 0.3 0.4 0.3 0.3 0.2. 0.2. 
30 0.3 0.3 0.1 0.1 0.1 0.2 
- - - 4.2 0.6 -6.2. 5.0 4.6 1.0 
Acetylsalicylic Acid. Part A 
Flask Numbers 
1 la 2. 2.a 3 3a 
5 2..7 2..2. 1.1 0.9 0.1 0.3 
M 10 1.3 1.3 1.0 1.0 0.1 0.1 
i 
n 15 0.9 1.0 0.7 0.8 0.0 0.0 
u 
t 2.0 0.5 0.7 0.8 0.8 0.0 0.0 
e 
s 2.5 0.6 0.4 0.7 0.7 0.1 0.0 
30 0.3 0.3 0.4 0.3 0.0 0.1 
D - - - - -5.9 4.7 4.5 0.3 0.5 
.........-
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Acetylsalicylic Acid. Part B 
Flask Numbers 
1 la 2 2a 3 3a 
5 2.7 2.6 2.3 2.3 0.3 0.3 
M 10 1.2 1.5 1.2 1.3 0.2 0.2 
i 
n 15 1.2 1.2 0.9 0.9 0.1 0.0 
u 
t 20 0.9 0.9 0.8 0.8 0.0 0.1 
e 
s 25 0.2 0.4 0.3 0.4 0.3 0.1 
30 0.2 0.2 0.3 0.2 0.1 0.2 
6.4 6.8 - - - -5.8 5.9 1.0 0.9 
Acetylsalicylic Acid. Part B 
Flask Numbers 
1 1a 2 2a 3 3a 
5 2.0 2.4 1.9 1.5 0.2 0.3 
M 10 0.8 0.5 0.8 1.0 0.2 0.2 
i 
n 15 1.0 0.9 0.8 0.7 0.1 0.0 
u 
t 20 0.7 0.7 0.8 0.7 0.0 0.0 
e 
s 25 0.5 0.5 0.7 0.8 0.2 0.3 
30 0.4 0.4 0.5 0.6 0.2 0.2 
- 5.4 - - 0.9 -5.4 5.5 5.3 1.0 
---
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C. Acetamidoantipyrine. Pa.rt A 
Flask Num be r 
1 la. 2 2a 3 3a 
5 2.2 2.3 1.8 2.0 0.2 0.3 
M 10 0.7 1.0 0.8 0.8 0.0 0.1 
i 
n 15 0.6 0.6 0.5 0.6 0.2 0.1 
u 
t 20 0.4 0.4 0.5 0.4 0.0 0.0 
e 
8 25 0.4 0.4 0.5 0.4 0.0 0.0 
30 0 .. 3 0.4 0.4 0.3 0.0 0.0 
4.6 - - - 0:4 -5.1 4.5 4.5 0.5 
Acetamidoantipyrine. Part A 
Flask Number 
1 1& 2 2a 3 3& 
5 2.3 2.5 1.7 2.1 0.3 0.1 
M 10 0 .. 7 0.7 1.0 0.7 0.1 0.2 
i 
n 15 0.5 0.9 0.5 0.5 0.0 0.0 
u 
t 20 0.6 0.7 0.5 0.7 0.0 0.1 
e 
s 25 0.4 0.3 0.2 0.3 0.2 0.0 
30 0.3 0.3 0.2 0.1 0.0 0.0 
- - - - - -4.8 5.4 4.1 4.4 0.6 0.4 
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Acetamidoantipyrine. Part B 
Flask Numbers 
1 la 2 2a 3 3a 
5 1.9 1.8 1.6 1.7 0.1 0.2 
M 10 1.1 1.1 0.9 0.9 0.2 0.1 
i 
n 15 0.9 0.8 0.9 0.6 0.1 0.2 
u 
t 20 0.7 0.8 0.5 0.7 0.1 0.1 
e 
s 25 0.5 0.5 0.6 0.5 0.1 0.1 
30 0.5 0.4 0.3 0.2 0.1 0.1 
5.6 - 4.'i 4.6 - -5.4 0.7 0.8 
Acetamidoa.n tiplrine. Part B 
Flask Numbers 
1 la 2 2a 3 3a 
5 2.7 2.4 1.6 1.7 0.2 0.2 
M 10 1.0 0.9 0.9 0.9 0.1 0.2 
i 
n 15 0.8 0.8 0.6 0.6 0.1 0.1 
u 
t 20 0.6 0.6 0.5 0.6 0.1 0.1 
e 
s 25 0.5 0.4 0.4 0.4 0.2 0.1 
30 0.4 0.5 0.6 0.7 0.1 0.1 
- - 4.6 - - -6.0 5.6 4.9 0.8 0.8 
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D. 3 .. HydroxyacetanUide. Part A 
Flask Numbers 
1 1a 2 2a 3 3a 
5 4.1 3.8 3.0 2.9 0.7 0.8 
M 10 0.7 0.8 0.9 0.8 0.0 0.1 
1 
n 15 0.5 0.4 0.7 0.6 0.1 0.1 
u 
t 20 0.4 0.4 0.5 0.6 0.2 0.1 
e 
s 25 0.3 0.5 0.4 0.4 0.1 0.2 
30 0.2 0.2 0.2 0.1 0.1 0.2 
- - - - - -6.l. 6.1 5.7 5.4 1.2 1.5 
3 -HY4roxxacet:anUlde. Part A 
Flalk Numbers 
1 la 2 2a 3 la 
5 4.2 4.5 3.4 3.2 0.5 0.6 
M 10 0.8 0.8 0.7 0.6 0.2 0.1 
i 
n 15 0.7 0.7 0.6 0.7 0.1 0.0 
u 
t 20 0.5 0.6 0.6 0.5 0.3 0.2 
e 
s 25 0.5 0.5 0.4 0.5 0.2 0.2 
30 .Q.:.! 0.2 O.l 0.2 0.1 0.1 
- - - - -7.1 7.3 6.0 5.7 1.4 1.2 
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3 ... HydroxyacetanUide. Part B 
Flask Number. 
1 la Z Za 3 3a 
5 Z.8 Z.5 1.9 1.8 0.2 O.Z 
M 10 1.4 1.3 0.9 1.0 O.Z 0.3 
i 
n 15 0.6 0.6 0.7 0.7 0.0 0.0 
u 
t 20 0.6 0.5 0.4 0.4 0.0 0.0 
e 
• 25 0.8 0.8 0.6 0.6 0.1 0.1 
30 0.6 0.5 0.4 0.4 0.0 0.0 
6.8 - - - - -6.2 4.9 4.9 0.5 0.6 
3 .. HydroxxacetanUide. Part B 
Flask Numbers 
1 la Z Za 3 3. 
5 Z.7 2..7 2..4 Z.2. 0.3 0.4 
M 10 1.4 1.1 0.6 0.7 0.0 0.1 
i 
n 15 0.8 0.7 0.7 0.7 0.1 0.0 
u 
t 200 0.5 0.5 0.5 0.6 0.1 0.1 
e 
s ZS 0.7 0.7 0.7 0.6 0.1 0.0 
30 0.7 0.7 0.6 0.6 0.1 0.0 
- - - - - 0.6 6.8 6.4 5.5 5.4 0.7 
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E. AcetoacetanUide. Part A 
Flask Numbers 
I la Z Za 3 3a 
5 3.0 2.0 3.1 2.6 0.1 0.4 
M 10 2.9 0.7 0.8 0.8 0.2 0.1 
1 
n IS 1.4 1.0 0.5 0.9 0.4 0.2 
u 
t 20 0.8 1.0 0.4 0.7 0.1 0.4 
e 
s 25 0.5 0.6 0.4 0.5 0.2. 0.4 
30 0.4 0.7 0.6 0.6 O.l 0.2 
- - - 6.1 - -9.0 6.0 5.8 1.2. 1.7 
AcetoacetanUtde. Part A 
Flask Numbers 
1 la Z Za 3 3a 
5 3.4 3.0 Z.2. 2.4 0.5 0.6 
M 10 0.9 0.8 1.1 1.0 0.2 0.1 
i 
n 15 0.6 0.8 0.6 0.8 0.1 0.2. 
u 
t 20 0.5 0.4 0.7 0.6 0.1 0.2. 
e 
8 25 0.5 0.6 0.7 0.8 0.1 0.1 
30 0.5 0.5 0.5 0.4 0.2. 0.2. 
- 6.1 - 6.0 - -6.4 5.8 1. Z 1.4 
..........-
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AeetoaeetanUide. Part B 
Flask Numbers 
1 la Z Za 3 3a 
5 3.3 3.1 Z.' 2.4 0.5 0.4 
M 10 0.9 1.0 0.9 1.0 0., 0.2 
i 
n 15 0.6 0.6 0.6 0.8 0.1 0.2 
u 
t 20 0.6 0.7 0.7 0.7 0.3 0.1 
e 
8 25 0.2 0.2 0.3 0.5 o. Z 0 .. 1 
30 0.4 0.3 0.2 0.2 0.1 0.1 
- - - 5.'6 - -6.0 5.9 4.9 1.4 1.1 
Aeetoaeetanilide. Part B 
Flask Numbers 
1 la 2 2a 3 3. 
5 3.4 3.4 2.0 1.8 0.3 0.2 
M 10 1.1 1.2 0.9 0.9 0.1 0.1 
1 
n 15 1.2 1.3 0.9 0.9 0.1 0.1 
u 
t 20 0.5 0.4 0.5 0.5 0.1 0.0 
e 
• 25 0.1 0.4 0.5 0.4 0.0 0.0 
30 0.1 0.3 O. Z 0.3 0.1 0.0 
- - - - - -6.4 7.0 5.0 4.8 0.7 0.4 
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F. N .Acetyl -p- Amlnopheno1. Part A 
Flask Numbers 
1 la 2- Za 3 3a 
5 Z.5 3.0 Z.2. 2..3 0.4 0.3 
M 10 1.3 1. Z 0.8 1.0 0.3 O.Z 
i 
n 15 0.6 0.6 0.6 0.7 0.2. 0.2. 
u 
t 2.0 0.4 0.4 0.6 0.6 0.1 0.1 
e 
s 25 0.3 0.3 0.5 0.4 0.2. 0.2. 
30 0.5 0.5 0.3 0.5 0.2. 0.1 
n ro - - - -5.0 5.5 1.4 1.1 
N ... Acetyl -p" Amlnophenol. Part A 
Flaak Numbers 
1 1a Z Za 3 3a 
5 Z.7 Z.5 2..3 1.8 0.3 0.4 
M 10 1.2. 0.9 0.5 0.7 0.1 O.Z 
1 
n 15 0.4 0.7 0.7 0.7 0.2. 0.2 
u 
.t 2.0 0.6 0.4 0.4 0.5 0.2. 0.1 
e 
a 2.5 0.5 0.3 0.5 0.4 0.1 0.1 
30 0.3 0.4 0.2. 0.2. 0.1 0.1 
- - - - - -5.7 S. Z. 4.6 4.3 1.0 1.1 
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N .. Acetyl -p- Aminophenol. Part B 
Flask Numbers 
1 la 2 2a 3 3a 
5 2.3 2.1 1.9 1.7 0.4 0.3 
M 10 0.9 0.9 0.5 0.8 0.3 0.2 
i 
n 15 1.0 1.0 0.7 0.7 0.2 0.2 
u 
t 20 0.6 0.9 0.7 0.6 0.3 0.1 
e 
s 25 0.6 0.6 0.6 0.7 0.1 0.1 
30 0.5 0.5 0.5 0.6 0.1 0.1 
- - - - -5.9 6.0 4.9 5.1 1.4 1.0 
N -Acetyl ... p .. Aminophenol. Part B 
Flask Numbers 
1 1a 2 2a 3 3a 
5 3.3 2.8 2.6 2.5 0.5 0.5 
M 10 0.7 1.1 0.9 0.9 0.3 0.2 
i 
n 15 0.7 0.7 1.0 0.7 0.3 0.2 
u 
t 20 0.7 0.6 0.9 0.8 0.1 0.1 
e 
s 25 0.4 0.3 0.3 0.5 0.2 0.1 
30 0.4 ~ 0.0 0.4 0.1 0.1 
- -6.2 5.9 5.7 5.8 1.5 1.2 
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G. P .. Acetphenetidine. Pa.rt A (using 10mI. in main fiask) 
Flask Numbers 
1 la Z 2a. 3 3a 
5 4.4 4.0 2..5 3.0 1.5 1.2. 
M 10 2.5 3.0 1.8 2.5 1.0 1.1 
i 
n 15 1.9 1..Z 1.6 1.9' 0.8 1.1 
u 
t 20 1.6 1.7 1.2 1.1 0.3 0.4 
e 
s 25 1. Z 1.1 1.3 0.8 0.6 0.2 
30 0.8 0.8 0.7 0.6 0.2. 0.1 
- - - - - -12.4 12.8 9.1 9.9 4.4 4.1 
P .. Acetphenetidine. Pa.rtA 
Flask Numbers 
1 la Z Za 3 3& 
5 4.3 4.1 3.4 3.2 1.9 1.9 
M 10 20.0 2.3 1.6 1.7 0.6 0.8 
I 
n 15 1.5 2..0 1.7 1.20 0.6 0.6 
u 
t 200 1.1 0.0 1.3 1.3 0.4 0.4 
e 
s 2.5 0.6 0.8 0.8 0.8 0.2 0.2 
30 0.6 0.6 0.8 0.7 0.0 0.2. 
- - - - - -10.1 9.8 9.6 8.9 3.7 4.1 
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P-Acetphenetldine. Part B 
Flask Numbers 
1 la Z Za 3 3a 
5 4.9 6.4 5.8 5.0 2.2 2.4 
M 10 3.3 3.3 2.6 2.9 0.6 0.5 
i 
n 15 2.4 2.8 1.7 0.9 0.6 0.8 
u 
t 20 1.1 1.4 1.2 1.3 0.5 0.4 
e 
s 2S 0.8 1. Z 0.9 0.5 0.3 0.2 
30 0.7 0.7 0.7 0.4 0.5 0.1 
- - - - 4.1 -13.2 15.8 12.9 11.0 4.4 
P:-Acetphenetldlne. Part B 
1 la 2. Za 3 3. 
5 5.8 4.1 2..3 1..7 1.0 1.3 
M 10 Z.3 Z.3 2.2 2.Z 0.7 0.8 
i 
n 15 1.0 0.8 1.2 1.6 0.8 0.2 
u 
t 20 0 .. 5 0.7 0.7 0.9 0.2 0.2. 
e 
s 1.5 0.3 0.4 0.6 0.7 0.4 0.2 
30 0.5 0.7 0.7 0.5 0,,1. 0.0 
- - - - - -10.4 9.0 7.7 8.6 3.3 2.7 
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IlL S!!Ge Three 
A. 4-Amlnoantipyrine. Part A 
Flask Numbers 
1 la 2. 2.a 3 3a 
5 2.0.8 2.0.1 16.7 17.0 0.3 0.2 
M 10 20.6 20.8 13.7 16.0 0.2. 0.1 
i 
n 15 16.9 16.5 12.6 14.7 0.1 0.1 
u 
t 20 10.3 10.8 U.l. 11.l. 0.0 0.1 
e 
s 25 9.1 9.6 8.0 7.5 0.0 0.0 
30 8.l. 7.9 1.7 9.3 0.1 0.1 
- - 69.9 - - 0:6 85.9 85.1 15.7 0.1 
4 .. Amlnoantipyrine. Part A 
Flask Number. 
1 la l. 2a 3 ]a 
5 2.1.0 2.3.6 15.2 15.3 0.1 0.2. 
M 10 18.6 16.3 13.4 13.3 0.1 0.1 
1 
n 15 17.1 14.5 13.3 13.4 0.0 0.0 
u 
t 2.0 9.4 9.5 7.7 1.9 0.0 0.1 
e 
• 25 10.1 9.6 8.1 8.7 0.1 0.1 
30 7.1 7.0 7.4 8.0 0.0 0.0 
- - 65.1 66.'6 - -83.3 80.5 0.3 0.5 
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4 ... Amlnoantipyrine. Part B 
Flask Numbers 
1 la 2 2& 3 3a 
5 23.9 2Z.2 17.2 15.5 0.1 0.1 
M 10 18.6 20.2 16.0 14. Z 0.1 0.1 
i 
n 15 16.7 16.4 14.6 14.9 0.0 0.1 
u 
t 2.0 8.0 8.4 12.5 12.7 0.0 0.1 
e 
s 25 8.7 9.2. 7.3 9.0 0.0 0.0 
30 7.6 8.4 7.5 9.4 0.0 0.0 
- - - - - -83.5 84.8 75.1 75.7 0.2 0.4 
4-Amlnoantlpydne. Part B 
Flask Numbers 
1 1& 2 Za. 3 3a 
5 21.1 24.1 18. <} 15.0 0.1 0.4 
M 10 21.0 21.0 16.3 16.0 0.2 0.1 
i 
ft 15 16. Z. 16.4 15.5 15.1 0.0 0.0 
u 
t 20 12.5 13.0 10.6 U.S 0.1 0.1 
~ 
s 25 10.5 10.0 9.5 10.1 0.0 0.0 
30 6.6 6.4 6.5 7.4 0.0 0.0 
- - - - - '0':6 87.9 90.9 77.3 75.1 0.4 
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B. AcetXlsallcyllc Add. Part A 
Flask Numbers 
1 la Z Za 3 3a, 
S 2..7 l.5 2.4 Z.5 0.5 0.3 
M 10 0.1 0.8 0.6 0.6 0.0 0.1 
i 
n 15 0.2. 0.4 0.3 0.3 0.0 0.0 
u 
t 20 0.4 0.4 0.4 0.4 0.0 0.0 
e 
s 25 0.3 0.4 0.3 0.3 0.1 0.0 
30 0.3 0.4 0.3 0.4 0.0 0.0 
- - - - - -4.6 4.9 4.3 4.5 0.6 0.4 
Acetylsa1icXlic:: Acid. Part A 
FlaakNumbera 
1 la 2. 2a 3 3. 
5 4.1 3.1 3.0 3.3 0.5 0.6 
M 10 0.5 0.4 0.6 0.6 0.1 0.3 
i 
n 15 0.3 0.2 0.3 0.3 0.0 0.0 
u 
t 20 0.2 0.2 0.2 0.2 0.1 0.0 
e 
a 25 0.1 0.1 0.2. 0.2 0.1 0.0 
30 0.1 0.1 0.2 0.3 0.1 0.1 
- - - - - -5 • .3 4.1 4.5 4.9 0.9 1.0 
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AcetxlsalicX1ic Acid. PartB 
Flask Numbers 
I la Z 2a 3 3a 
5 3.5 3,,6 2.7 2.3 0.2 0.2. 
M 10 0.6 0.5 0.6 0.5 0,,1 0.1 
i 
n 15 0.3 0.3 0.3 0.3 0.1 0.0 
u 
t 20 0.4 0.5 0.4- 0.4 0.0 0.1 
e 
s 25 0.2 O.l 0.3 0.3 0.0 0.0 
30 O.Z 0.3 0.2 0.2. 0.1 0.0 
- - - - - -5.Z 5.4 4.5 4.0 0.5 0.4 
AcetxlsaUcxlic Acid. Part B 
Flask Numbers 
1 la 2 2a 3 3& 
5 3.4 3.4 2..6 2.3 0.2 0.1 
M 10 0.5 0.5 0.4 0.4 0.1 0.2. 
1 
n 15 0.4 0.5 0.4 0.4 0.0 0.1 
u 
t ZO 0.3 0.3 0.4 0.2. 0.0 0.0 
e 
8 25 0.4 0.2 0.3 0.4 0.1 0.0 
30 0.3 0.3 0.4 0.4 0.1 0.1 
- - - - - -5.3 5. Z 4.5 4.1 0.5 0.5 
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C. Acetamidoantipyrine. Part A 
Flask Numbers 
1 la I. la 3 3a 
5 l.Z 1.9 1.4 0.9 O.z. O.l 
M 10 0.8 0.8 1.1 1.4 0.3 0.1 
i 
n 15 0.1 0.7 0.5 0.5 O.l. 0.1 
u 
t lO 0.7 0.7 0.6 0.9 0.1 0.1 
e 
8 l5 0.5 0.4 0.3 0.5 0.1 0.1 
30 0.7 0.7 0.6 0.1 0.0 0.0 
n - - - - 0':1' S.Z 4.5 4.9 0.9 
Acetamidoantlpyrine. Part A 
Flask Numbers 
1 la l la 3 3a 
5 l.3 l.O 1.8 1.8 0.3 O.l 
M 10 0.6 0.5 0.5 0.6 0.0 0.0 
i 
n 15 0.5 0.5 0.5 0.5 0.1 0.1 
u 
t lO 0.5 0.7 0.5 0.6 0.0 0.0 
e 
s Z5 0.6 0.6 0.6 0.7 0.0 0.0 
30 0.5 0.5 0.4 0.5 0.1 0.0 
- - - - - -5.0 4.8 4.3 4.7 0.5 0.3 
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Acetamldoantll?yrlne. Part B 
Flask Numbers 
1 la 2. 2a 3 3. 
5 3.7 4.4 4.0 4.4 1.2 1.1 
M 10 1.0 1. Z 0.7 0.8 0.1 0.1 
i 
n 15 0.6 0.6 0.5 0.5 0.2. 0.1 
u 
t 2.0 0.5 0.3 0.3 0.3 0.1 0.0 
e 
s 2S 0.3 0.4 0.2 0.3 0.0 0.0 
30 0.2 O • .3 0.2 0.2 0.1 0.1 
- - - 6.S - -6 • .3 7.2 S.9 1.7 1.4 
Acetamldoantlpyrine. Part B 
Flask Numbers 
1 la Z Za 3 3a 
S 4.4 4.7 3.1 2..1 1.0 0.8 
M 10 0.8 0.1 1.1 1.0 0.3 0.3 
1 
n IS 0.7 0.1 0.4 0.5 0.0 0.0 
u 
t 20 0.4 0.4 0.6 0.4 0.0 0.0 
e 
8 25 0.2 0.2 0.3 0.3 0.1 0.1 
30 O. :5 0.2 0.3 0.4 0.1 0.1 
- 6.9 - - - -6.8 S.8 5. :5 1.5 1.3 
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D. 3·H ydroxyacetauUide. Part A 
Flask Number. 
1 la Z Z& 3 3. 
5 2.3 2.0 1.9 1.6 0.2. 0.4 
M 10 0.9 1.0 0.9 1.1 0.1 0.1 
i 
n 15 0.8 0.7 0.5 0.4 0.1 0.1 
u 
t 20 0.8 0.9 0.4 0.4 0.1 0.0 
e 
• 2.5 0.5 0.5 0.6 0.5 0.0 0.0 
30 0.4 0.4 0.4 0.4 0.0 0.0 
- - - - - 0.6 5.7 5.5 4.7 4.4 0.5 
3 ... H yc!roxracetanUide. Part A 
Flask Numbers 
1 la Z Z& 3 3& 
5 4.5 4.2. 3.3 3.1 1.1 1.0 
M 10 0.8 0.8 0.5 0.5 0.1 0.0 
i 
n 15 0.6 0.5 0.5 0.7 0.0 0.1 
u 
t 2.0 0.5 0.6 0.4 0.5 0.0 0.0 
e 
• 2.5 0.4 0.6 0.6 0.6 0.0 0.0 
30 0.3 0.2. 0.3 0.3 0.0 0.0 
- - - - - -7.1 6.9 5.6 5.7 1.2. 1.1 
"-£~~~~:,,,,'i.\,~.M:dii.ta:L;2a:. ..... ..J'~c~,;;~'W:.,1i¥"~:;-~;".~, ~"'.<l'.;:o~'~':.~_ A·'';'~-<·_''':'''''''-_ ", .. -:1 
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3 .. aydroxyacetanUide. Part B 
Flask Numbers 
1 la 2. 2.a 3 3a 
5 4.2. 3.9 3.1 3.0 1.1 0.9 
M 10 0.9 0.8 0.6 0.6 0.3 0.1 
i 
n 15 0.6 0.6 0.6 0.5 0.1 O.Z 
u 
t ZO 0.5 0.6 0.4 0.4 0.0 0.0 
e 
• 2,5 0.4 0.4 0.6 0.7 0.0 0.1 
30 0.4 0.3 0.3 0.2. 0.1 0.0 
- - - - - -7.0 6.6 5.6 5.4 1.6 1.3 
3 -Hy<!roxy!cetanUide. Part B 
Flask Numbers 
1 la 2- z. 3 3a 
5 3.8 4.0 3.0 Z.8 0.5 0.7 
M 10 0.8 0.8 0.5 0.7 0.1 0.1 
1 
n 15 0.6 0.6 0.6 0.4- O.z. 0.1 
u 
t z.O 0.4 0.4 0.5 0.5 0.1 0.1 
e 
• z.5 0.3 0.4 0.4 0.4 0.1 0.1 
30 0.4 0,4 0.4 0,5 0.0 0.1 
- - - - - -6.3 6.6 5.4 5.3 1.0 1. Z. 
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E. AcetoacetanUide. Part A 
Flask Numbers 
1 la 2 2a 3 3. 
5 3.5 2.9 2.8 3.1 0.4 0.2 
M 10 1.0 1.0 0.7 0.7 0.1 0.1 
i 
n 15 0.5 0 .. 5 0.3 0.4 0.0 0.1 
u 
t 20 0.4 0.4 0.2 0.2 0.1 0.0 
e 
8 Z5 0.4 0.4 0.3 0.4 0.0 0.0 
30 0.2. 0.2 0.1 0.2 0.0 0.0 
6.0 - - - 0:6 -5.4 4.4 5.0 0.4 
Acetoaeetanillde. Part A 
Flask Number s 
1 1a 2. 2.a 3 3a 
5 3.4 3. Z. 2.3 2.3 0.2 0.1 
M 10 0.9 1.0 0.6 0.8 0.0 0.1 
I 
n 15 0.4 0.4 0.4 0.4 0.0 0.0 
u 
t 2.0 0.5 0.5 0.3 0.2 0.0 0.1 
e 
8 25 0.4 0.5 0.3 0.3 0.0 0.0 
30 0.2 0.2 0.2 0.3 0.0 0.0 
- - - - - -5.8 5.8 4.1 4.3 0.2 0.3 
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AcetoacetanUide. Part B 
Flask Numbers 
1 1a Z 2a 3 3a 
5 4.9 5.1 3.9 3.5 0.8 1.1 
M 10 0.7 0.9 0.6 0.7 0.2 0.1 
i 
n 15 0.5 0.5 0.5 0.3 0.0 0.0 
u 
t ZO 0.4 0.6 0.4 0.6 0.1 0.0 
e 
8 ~5 o.~ O.Z 0.3 O.~ 0.0 0.0 
30 0.4 0.4 0.3 0.3 0.1 0.1 
- - - n - -7.1 1.7 6.0 1.2 1.3 
AcetoacetanUlde. Part B 
Flask Nwnbera 
1 la 2 2a 3 3. 
5 4.9 5.2 3.3 3.3 0.6 0.7 
M 10 0.8 0.9 0.7 0.8 0.2 0.2 
i 
n 15 0.4 0.4 0.5 0.4 0.0 0.0 
u 
t zo 0.3 0.4 0.4 0.3 0.0 0.0 
e 
• 25 0.2 0.3 0.3 0.3 0.0 0.0 
30 0.4 0.3 0.4 hl 0.1 0.1 
- - - - -7.0 7.5 5.6 5.4 0.9 1.0 
I --t ..1 
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F. N -Acetll -p- Amlnopbenol. Part A 
Flask Numbers 
1 la 2. 2.a 3 3a 
5 3.5 3.3 2..7 2..9 0.4 0.3 
M 10 0.7 0.6 0.8 1.1 0.2. 0.2. 
1 
n 15 0.5 0.5 0.5 0.4 O.z. 0.2. 
u 
t z.o 0.3 0.3 0.2. 0.4 0.2. 0.1 
e 
• 2.5 0.2. 0.3 0.2. 0.3 0.1 0.1 
30 0.3 0.3 0.4 0.4 0.1 0.1 
- - - - - -5.5 5.3 4.8 5.5 1. Z 1.0 
N -Acetll -p- Aminophenol. Put A 
FlaakNumbers 
1 la 2. 2.a 3 3a 
5 3.8 3.3 3.1 3.3 0.4 0.5 
M 10 0.8 0.7 0.8 0.9 0.2 0.3 
1 
n 15 0.6 0.6 0.5 0.4 0.3 0.1 
u 
t 2.0 0.5 0.4 0.2. 0.2. 0.2. 0.0 
e 
s 2.5 0.3 0.5 0.5 0.5 0.1 0.1 
30 0.2. 0.2. O.z. 0.2. 0.1 0.1 
6.2. - - - - -5.7 5.3 5.5 1.3 1.1 
92. 
N ... Aeetyl ... p- Aminopbenol. Part B 
Flask Number. 
1 1& Z Za. 3 3a 
5 4.5 4.3 2..7 2.8 0.6 0.7 
M 10 1.0 0.9 0.6 0.5 0.4 0.3 
i 
n 15 0.5 0.5 0.4 0.5 0.2. 0.0 
u 
t lO 0.3 0.3 0., 0.3 0.2. 0.1 
e 
• 25 0.4 0.3 0.3 0.3 0.0 0.1 
30 O. ;a 0.3 0.3 0.3 0.1 0.0 
- n - - - -6.9 4.5 4.7 1.5 1. Z. 
N .. AeetIl -p- Aminophenol. Part B 
Flask Numbers 
1 la , 2.a 3 3& 
5 4.0 4.0 3.2 2..8 0.8 0.9 
M 10 0.7 0.8 0.6 0.5 0.2. 0., 
i 
n 15 0.2 0.3 0.3 0.3 0.0 0.0 
11 
t 20 0 .. 3 0.2, 0.2 0.1 0.0 0.0 
e 
• 2,5 0.4 0.4 0.3 0.3 0.0 0.1 
30 0.3 0.4 0.20 0.20 0.1 0.0 
- - - - - -5.9 6.1 4.8 4.2. 1.1 1.2. 
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F. P -Acetphenetidine. Pa.rt A 
Flask Numbers 
1 1a 2 2.a. 3 3a 
5 5.0 4.0 5.5 5.0 Z.Z Z.3 
M 10 1.5 1.7 0.8 0.8 0.5 0.7 
i 
n 15 0.7 0.9 0.8 0.7 0.4 0.2 
u 
t 2.0 0.6 0.4 0.4 0.3 0.1 0.2. 
e 
s 2.5 0.7 0.7 0.8 0.8 0.1 0.1 
30 0.4 0.4 0.1 0.2. 0.1 0.1 
- - - - - -8.9 8.1 8.4 7.8 3.4 3.6 
P.Acetphenetidine. Part A 
Flask Numbers 
1 la Z 2.a 3 3. 
5 5.5 6.0 5.5 4.9 3.7 3.6 
M 10 1.3 1.9 0.5 0.9 o.z 0.2. 
1 
n 15 0.6 0.6 0.6 0.3 0.1 0.1 
u 
t ZO 0.7 0.5 0.7 0.4 O.Z 0.2. 
e 
• Zs 0.6 0.6 0.6 0.4 0.1 0.1 
30 0.3 0.3 0.6 0.5 O.Z 0.2. 
- - - - - -9.0 9.9 8. S 7.4 4.5 4.4 
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P .. Acetphenetidine~ Part B 
Flask Numbers 
1 1a Z. 2.a 3 3. 
5 5.1 5.1 4.4 5. Z. 3.0 3 • .2 
M 10 2.4 2.5 2.3 2.3 0.5 0.6 
i 
n 15 0.8 0.7 0.1 0.7 0.4 0.3 
u 
t 2.0 0.5 0.9 0.4 0.6 0.2 0.2. 
e 
s 2: 0.6 0.5 0.5 0.4 0.1 0.1 
30 0.5 0.5 0.3 0.4 0.0 0.0 
- - - - - -10.5 10.2 8.6 9.6 4.2 4.4 
P,.Acetphenetidlne. Part B 
Flask Numbers 
1 la 2 2a 3 3a 
5 5.0 5.8 3.5 5.4 3.0 3.3 
M 10 2.4 2..4 3. Z. l.2. 0.5 0.6 
i 
n 15 1.2. 1.1 0.8 0.8 0.3 0.4 
u 
t 2.0 0.6 0.6 0.3 0.5 0.2. 0.4 
e 
s 2.5 0.7 0.6 0.6 0.6 0.2. 0.2 
30 0.7 0.8 0.6 0.8 0.2. 0.2. 
- - - - - -10.6 U.3 9.0 10.3 4.4 5.1 
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CHAPTER FIVE 
DISCUSSION 
The primary purpose of this body of reaearch is to gain insight 
into the posalble mode of action of antipyretic compounds. This was ac-
complished through a series of experiments designed to determine if cer-
ta.in of these compounds act as beta carboxylase models in the body, and 
further to see if incubation with yeast and/or liver has any effect on their 
activity in this respect. 
The finding8 of stage one Bubstantiate previous study and seem 
to support the concept of Akamatsu and Fukwia. These men were the first 
to observe that a prerequisite for a compound to act as a beta carboxylase 
model appears to be the presence of an acetoacetic residue within the 
structure of the compound. The free amino group in the alpha carbon 
position seems to be the key to the mechanism ... s was stated earlier in 
the literature review, which may be to increase the affinity between the 
catalyst and 8ubstrate. 
4-aminoantipyrlne 18 the only compound tested which haa this 
structural component, and it was found to be the only one to exhibit sub ... 
stantial catalytic activity upon teaUng. This compound is ten to fifteen 
times more potent than any of the others tested. 
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Incubation with yeast. performed in the second stage. appeared 
to have a negUgible effect on the catalytic activity of these compounds. 
Liver. in addition. produced results indicating a lack of influence of this 
tissue on tbese compounds with respect to affecting a transformation to a. 
carboxylas. model. In both cases yea't and liver. there was no Significant 
altera.tion In the progress of the rea.ction which would indicate that either 
substance had changed these compounds in any way. It must be remembered. 
however. that the purpose of this program is very specific in nature, and 
this does not mean to imply that no change did occur. As a matter of fact. 
these compounds might stUI be found to act as enzyme models 1ft the body 
with further investigation. It is very important to note at this time. how-
ever, that liver tissue does not cause a transformation of these antipyretic 
compounds to beta carboxylase models following twenty.four hours of 
incubation. 
The specificity of enzyme models is ~n,empllfled by comparing the 
catalytic activity of 4 .. aminoantipyrine and acetamidoantlpyrlne with their 
structural arrangement. These compounds are very simUar in structure, 
differing on! y in the nature of the group in the alpha carbon position, This 
difference is sufficient, however, to permit one, 4-amlnoantlpyrlne, to act 
as a carboxylase model and not the other. 
An a.ttempt to correlate structural architecture with catalytic ac-
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tlvity as Kaneko did might be somewhat misleading for all of the compounds 
were found to be very slmUar in their abUity to catalyze the decarbox.yla-
tion reaction. The compounds listed according to their abUlty to catalyze 
the reaction are: 4 .. aminoantipyrine, P-a.cetpbenetidine. acetoacetaniUde, 
3 .. bydroxyacetanUlde, acetylsalicylic acid, N-acetyl p ... aminopbenol and 
acetamidoantipyrine. 
4 ... aminoantlpyrine is known to have barmful side effects wbich 
have caused its 'I •• to be reduced to a considerable degree. Knowing that 
this compound act. as a beta carboxylase model and there is definite evi-
dence that the otbers may not, a further research program might attempt 
to correlate this activity with tbe slde effect produced. If succes sful, this 
mlgbt open the doors to t'indlng the method of eliminating the cause of the 
side effects witbout damaging the antipyretic property. Another worthy 
area. of investigation would be to determine if otber biologic media can 
affect tbis transformation in tbese compounds to particula.r enzyme models. 
Thinking along these lines of further research activity in the area. 
of enzyme models, it should be noted that this concept of identifying the ac-
tion of therepeutic agenta with that of an enzyme model is quite unique. 
Thus, the field is wide open in thia regard. This concept is 80 general that 
it can and should be appUed to many different pharamacologic agents as a 
posaible mode of action. 
CHAPTER SIX 
SUMMARY 
Experiments were performed on seven representative antipyretic 
compounds in au a.ttempt to determine if these compounds act as beta car-
boxylase models. as would be evidenced by their abUity to increase the rate 
of decarboxylation of acetoacetic acid. The rate of the reaction was de-
termined by measuring the pressure dlfferential produced by the C02 given 
off at 5 minute intervals for 30 minutes. This was accomplbhed through 
the use of the Warburg respirometer. The wat.r bath of the apparatus was 
adjusted to 37°. Previous study has revealed that one of these compounds. 
4-amlnoantipyrine. does exhibit this property. Ea.ch of tbese compounds 
was also submitted first to yeast and then to liver incubation at 370 for 2.4 
bours to determine if either substance affected a change in their chemistry 
to beta carboxylase enzyme models. 
Tbis experimen.tal program revealed tbe following: 
1. Slx of the seven antipyretic ccmpounds do not show sub-
stantial catalytic activity in the decarboxylation to a 
marked deg!"ee. 
2.. 4-AminoanUpyrine ca.talyzed the decarboxylation to a 
marked degree. 
3. Incubation with yeast and liver appeared to have little 
effect on their abUlty to catalyze the reaction. 
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4. Little difference wa.s noted in the rate of the decarboxy-
la.tion with any of the compounds after either incubation 
process as compared with before incubation. 
105 
BIBLIOGRAPHY 
Akamatsu, S •• tlBeta-Carboxylase Model, It The Journal of Biochemistry, 
vol. 37. pp. 65 - 72 (1950) 
Barbour, H. t "Antipyretics It n Archives of Internal Medicine. vol. 24, 
pp. 611 ... 616 (1919) 
Barbour, H •• "Antipyretic. U Acetylsalicylic Acid and Heat Regulation In 
Normal Individual.," Archives of Internal Medicine, vol. 2,4, 
pp. 616 - 61.4 (1919) 
Barbour. H., "Antipyretics m Acetylsalicylic Acid and Heat Regulation In 
Fever Cases," Archive. of Internal Medicine, vol. 24, pp. 624 ... 630 
(1919) 
Beniya, K. t "Uber Dle Katalytiscbe Decarboxylierung Del' Beta Ketosaure, tI 
The Journal of Biocbemistrl, vol. 20, pp. 451 ... 463 (1934) 
Bogert, M. T.. It Preparation of 5 ... AmlnouracU and Some of Its Deriva-
tives, It Journal of the American Chemical Society, vol. 55, p. 1667 
(1933) 
Brodie, B. B •• "The Fate of Acetophenetidine (phenacetin) In Man and 
Methods For th"'!l Estimation of Acetophenetidine and Ita Metabolites 
In Biologic Materials, If Journal of Pharmacology and E!perimental 
Theraeutic., vol. 97. p. 58 (1949) 
Brodie, B. B •• ttThe Fate of Antipyrine In Man, tI Journal of PharmacoloSl 
and E!perimental Therapeutic., vol.98, p. 97 (1950) 
Brodie, B. B.» nThe Fate of Aminopyrine In Man and Method. For the 
Estimation of Aminopyrine and Its Metabolites In Biologic Material," 
Journal of Pharmacolosy and E!Eerlmental Therapeutics, vol. 99. 
p. 171 (1950) 
Brodie. B. B., and Axelrod, J., tiThe Fate of AcetanUide In Man, U 
Journal of PharmacoloSl and E!e!rtmental Therapeutics, vol. 94, 
p. 29 (1948) 
106 
107 
Boreus. L. 0., and Sandberg, F •• "Compa.rison of Some Pharmacologic 
Effects of Acetophenetidine and N ... acotyl p-aminophenol, ft Acta, 
Phl.iol. Scand •• vol. 28, p. z61 (1953) 
Cadavleco, R. D., "Carboxylase," Acta. Ct..nte Venezolanna, vol. 6, 
pp. 140 .. 146 (1955) 
Cardon, L •• ot. al., "Value of Aminopyrine," Annals of Internal Medicine, 
vol. 48, p. 616 (1958) 
Cramer, F., and Kampe, W. t "Catalysis of Decarboxylation By Means of 
Cyclodextrlns." Tetrahedron Letters,1 pp. 353 .. 356 (1962) 
Domenioz, R., "Pharmacotherapeutic Development of Antipyretics .. 
Analgetics. tJ Naunp .. Schmiedeberss Arch. ExpU.. Pa.thol. Pharma-
kol., vol. 225, pp. 3 .. 11 (1953) 
Graullch, R •• "The Mechanism of Action of Certain Antipyretic Com-
pounds," Presse Med •• vol. 62, p. 830 (1954) 
GroUman, A.. Pbarmacolosr and Theraeeutics, Philadelphia, Lea. and 
Feblger. 1962 
Grossmann, V •• "Use and Misuse of Analgetics and Antipyretics," Prakt 
Lekar, vol. 40, pp. 918 ... 923 (1960) 
., 
Guerra Perez-Carral, F •• and Barbour, H. 0 •• nThe Mechanism of 
Aspirin Antipyresis in Monkeys." Journal of Pha;rmacology and 
~!p!rimental Thera.:e!utlcs, vol. 79. p. 55 (1943) 
Guerra Perez .. Carral, F. and BrobeCk, J. R., "The Hypotha.lmic Control 
of Aspirin Antipyresis In Monkeys,n Journal of PharmacoloSl and 
E!pertmental Theraee"tics, vol. 80. p. 209 (1944) 
Kaneko, S •• uUber Die Katalytlsche Decarboxyllerung Del" Beta Ketosaure, It 
Journal of Biochemistry, vol. Z8 pp. 1 .. 18 (1938) 
Kobaya.sche. C.. HUber Del" Extraction Der Phosphatase Und Del" Ca.rboxy-
lase ner He!e." Journal of Biochemistry, vol. Z4, pp. 369 .. 387 (1936) 
Kobozev, N. L t "Mechanism of Catalysis m Valence and Energy Forms of 
Keterogenesis and Enzyme Ca.talysis, It Zhur. Fig. Khlm •• vol. 34. 
pp. 1443 - 1458 (1960) 
108 
Kuga t T •• nObel' Die Katalytische Decarboxylierung Del' Seta Ketocarbon-
saure," Journal of Biochemistry, vol. 35, pp. 2.93 - 305 (1941) 
Langenbeck, W •• ItFermentmodeUe, It Erg.bineBBe Del' Enzymforschung, 
vol. 2., pp. 314 - 335 (1933) 
Langenbeck. W. and Fittkau. S •• HOrganlc Catalysts xxxm Peroxidase 
Activity of Various Oxyhemoglobins," Chern. Ber •• vol. 87. pp. 501 .. 
505 
Matsumoto. S.. tlOrganic Catalysts I Reaction Kenetics of the Amine 
Catalyzed Decarboxyla.tion of Acetoacetic Acid, It Tech. Bull. Kagawa 
Agr. Coll. vol. 5, p. 393 (1953) 
Mix. H •• "Organic Ca.talysts XXXV Synthetic Dehydrase. 6 Synthetic 
Carboxylasest tI Anne vol. 592.. pp. 146 - 160 (1955) 
Pedereen, J. K. t uThe Decomposition of Alpha. ... NttrocarboxyUc Acid With 
Some Remarks on the Decomposition of Beta Ketocarboxylic Acids, It 
Journal of Physical Chemistrl, vol. 38, p. 559 
Pedersen. J. K.. "Hydrolysis of Acetoacetate and the Decarboxylation of 
Acetoacetic Acid in Strongly Acid Solution, It Acta. Chern. Scand.. 
vol. IS, pp. 1718 • 172.2. (1961) 
ProUt. E., "Method of Preparing Antipyretic Analgetic and Anaathetlcally 
Active Materials, H Chern. Tech., vol. 5 f p. 393 (1953) 
Sakurai, H., nprogress in Antipyretics and Pharmacology," Sogo Rtnsko, 
vol. 11. pp. 819 - 826 (1962) 
Schadt, R., Becker, E., Mc Laren. A.. n Enzyme Models n Kenetics of 
An Artificial Carboxylase Catalysis. tt Journal of PbIsical Chemistry, 
vol. 56722 .. 26 (l95Z, 
Schiro, T. and Skimoda, C., "Formation of Acetone.Serles Compounds By 
AspergUlu.s Oryzae D Carboxylase and CarboUgase of A Oryzae, u 
Nippon Nosei-Kagaku Kaeschi, vol. 29. pp. 317 - 321 (1955) 
Smith, P. K •• Acetophenettdine .. A Critical Biosraphical Review, New 
Haven, 1957 
109 
Stainler, C., "Analysis of Antineuralgic and Antipyretic Mixtures, tt Jour. 
Pharm. Belg •• vol. 8, pp. 3 - 11 (1953) 
Westhelmer, F. H •• and HamUton, G. A •• uMechanism of the Enzymic 
Decarboxylation of Acetoacetate. It Journal of the American. Chemical 
Society, vol. 81, pp.6332 '* 6333 (1959) 
W idm ark. E. t "The Kenetics of Ketonic Decomposition of Acetoacetic 
Acid," Acta Medica Scandlnavica., vol. 53, p. 393 (1920) 
W idm ark, E. and Jeppsson. C. A •• !tEln Definieater Organlschel" 
Katalysator Mit Wasseratoffeonoptimum, U Scandinavlaches Archlv 
fur Phlalologic, vol. 42, pp. 43·. 61 (1921) 
APPROVAL SHEET 
The thesis submitted by Dr. Jay Alan Mc Ma.bon has been read 
and a.pproved by three members or the Department of Oral Biology. 
The £i~ copies have been eX8.1nined by the Director of the 
thesis and the signature which appea.rs below vorUies the fact that any 
necessary changes have been incorporated, and that the tbesis is now 
given final approval with reference to content, lorm. a.nd mecha.nical 
accura.cy. 
The thesis Is therefore accepted in partial fu1£Ulment of the 
requirements for the Degree of Master of Selence. 
, 1-. ! 
I:' 
I \:; 
.~.~~~~~~~ o~c\~d~'~~; i~ ! 
